GCC Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and amp; Autoimmune Disorders, Rheumatoid Arthritis, Others)- Forecast to 2035

GCC Biosimilar Contract Manufacturing Market Overview:

As per MRFR analysis, the GCC Biosimilar Contract Manufacturing Market Size was estimated at 227.54 (USD Million) in 2023. The GCC Biosimilar Contract Manufacturing Market Industry is expected to grow from 270.55(USD Million) in 2024 to 1,000 (USD Million) by 2035. The GCC Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 12.62% during the forecast period (2025 - 2035).

Key GCC Biosimilar Contract Manufacturing Market Trends Highlighted

Several significant trends are presently being driven by regional healthcare needs and government initiatives in the GCC Biosimilar Contract Manufacturing Market. The growing demand for affordable biologics in the GCC healthcare sector is a significant market driver. The development of biosimilars is being actively supported by countries such as the UAE and Saudi Arabia in order to ensure that patients have access to effective remedies without the financial burden of high prices, as healthcare costs continue to increase.

This initiative is consistent with the Vision 2030 framework in Saudi Arabia, which is designed to improve healthcare services and diversify the economy. Countries are concentrating on the development of robust manufacturing capabilities in the GCC market, which is resulting in the capture of opportunities. This initiative is driven by the wish to reduce dependence on foreign suppliers, as well as to promote innovation and create local employment in the pharmaceutical industry. Additionally, the prevalence of collaborations between local firms and international biopharma companies is increasing, which facilitates the transmission of knowledge and expedites technological advancements in biosimilar production.

Recent trends suggest that the Gulf Cooperation Council (GCC) countries are increasingly interested in regulatory harmonization, which is intended to simplify the biosimilar approval process. Qatar and Oman are among the nations that are striving to enhance their regulatory frameworks in order to facilitate the entry of manufacturers into the market.In general, these trends suggest a dynamic shift in the GCC Biosimilar Contract Manufacturing Market, which is driven by a combination of demand for cost-effective healthcare solutions, local manufacturing initiatives, and improved regulatory environments. Ultimately, this transition positions the region as a competitive player in the global biosimilars landscape.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

GCC Biosimilar Contract Manufacturing Market Drivers

Rising Demand for Cost-Effective Biologics

The GCC Biosimilar Contract Manufacturing Market Industry is experiencing significant growth due to the rising demand for affordable biologics. With the increasing prevalence of chronic diseases, healthcare providers and patients are seeking cost-effective alternatives to expensive biologic treatments. A report by the World Health Organization indicates that the prevalence of chronic conditions such as diabetes and cardiovascular diseases in the GCC region has increased by 65% over the last decade.This trend highlights the urgent need for biosimilars, which provide comparable efficacy at a lower price point. Leading pharmaceutical companies like Pfizer and Amgen are investing in biosimilar development in the GCC region to meet this demand, further solidifying the market's growth.

Government Initiatives Supporting Biosimilars

Governments across the GCC are actively promoting the development and use of biosimilars as part of their healthcare strategies. Initiatives like the National Health Strategy in Saudi Arabia aim to enhance healthcare outcomes by increasing access to effective treatments, including biosimilars. By 2025, the Saudi government plans to increase the local production of pharmaceuticals by 50%, which includes biosimilars. This policy not only supports local manufacturers but also encourages foreign investments, creating a beneficial environment for the GCC Biosimilar Contract Manufacturing Market Industry.

Expanding R&D Investments in Biologics

The GCC region has seen a surge in Research and Development (R&D) investments in the biologics sector, which is a key driver for the GCC Biosimilar Contract Manufacturing Market Industry. According to a report from the Dubai Science Park, there has been an increase of over 40% in R&D funding for health innovation in the UAE and neighboring countries within the last three years. This increase is attributed to the collaboration between private sectors and governmental bodies, further strengthening the infrastructure necessary for biosimilar development and production.

Increasing Health Insurance Coverage

The expansion of health insurance coverage in the GCC region is making biologics more accessible to patients, particularly biosimilars. The GCC countries, especially the UAE and Saudi Arabia, have seen health insurance penetration rates increase, reaching 85% in urban areas. This growth is driving the demand for affordable treatment options like biosimilars, as more patients are now covered for their healthcare expenses. Insurance companies are recognizing the value of biosimilars due to their lower costs compared to reference biologics, thus promoting the adoption of the GCC Biosimilar Contract Manufacturing Market Industry and enhancing market growth.

GCC Biosimilar Contract Manufacturing Market Segment Insights:

Biosimilar Contract Manufacturing Market Product Insights

The GCC Biosimilar Contract Manufacturing Market has demonstrated significant potential, particularly within the Product segment, which encompasses vital areas such as Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. Recombinant Non-glycosylated Proteins play a crucial role in various therapeutic applications due to their simplified structure, which makes them easier to produce and purify, thereby driving efficiency in manufacturing processes. This segment attracts considerable interest as pharmaceutical companies seek cost-effective alternatives for biologic treatments, leading to an increase in demand for contract manufacturing services that specialize in these protein types

.On the other hand, Recombinant Glycosylated Proteins are recognized for their complex structures that mimic human proteins, which enhance their efficacy and safety profiles in clinical settings. Their significance in the market stems from the growing pressure to create biosimilars that can compete with innovator biologics, thereby providing patients with affordable treatment options while ensuring that the products meet rigorous regulatory standards. The GCC region has been strategically investing in biotechnology research and development, facilitating a conducive environment for advances in these protein types and contract manufacturing capabilities.

As a result, market players are increasingly turning to GCC-based manufacturers to leverage their expertise in biologics, thereby creating a dynamic competitive landscape characterized by innovation and collaboration among stakeholders. The overall focus on improving healthcare access through the production of biosimilars, combined with supportive governmental policies, positions the Product segment as a pivotal area of growth within the broader GCC Biosimilar Contract Manufacturing Market, reinforcing the region's commitment to establishing itself as a global hub for biopharmaceutical development.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Biosimilar Contract Manufacturing Market Production Technology Insights

The Production Technology segment of the GCC Biosimilar Contract Manufacturing Market plays a vital role in the overall industry landscape as it encompasses the methodologies and processes utilized in the production of biosimilars. This segment can be classified into Mammalian and Non-Mammalian technologies, both of which contribute significantly to the GCC market. Mammalian cell culture systems are well-regarded for their ability to produce complex proteins that closely mimic human biological processes, making them essential for the development of high-quality biosimilars.

These systems dominate the market due to their superior post-translational modifications and higher yield of functional proteins. On the other hand, Non-Mammalian systems, including microbial fermentation, offer advantages in terms of cost-effectiveness and faster production times, presenting a compelling alternative for certain biosimilar applications. The choice of production technology impacts factors such as scalability, regulatory compliance, and production costs, thus influencing the strategic decisions of contract manufacturers in the GCC.

As the demand for biosimilars continues to grow, understanding these production technologies will become increasingly important, offering a variety of opportunities and challenges in meeting both regulatory requirements and patient needs in the region.

Biosimilar Contract Manufacturing Market Application Insights

The Application segment of the GCC Biosimilar Contract Manufacturing Market showcases a diverse array of healthcare needs that are being addressed through biosimilars. This segment is notably driven by the increasing prevalence of chronic diseases, particularly in Oncology, which has emerged as a critical area due to the high demand for effective and affordable cancer treatments. Blood Disorders, including conditions like anemia and hemophilia, also highlight the significance of biosimilars, providing cost-effective alternatives to expensive biologics.

Additionally, the growing recognition of Growth Hormonal Deficiency among children and adults is pushing for more biosimilar options in this category, reflecting the changing healthcare landscape in the region. Chronic and Autoimmune Disorders, along with Rheumatoid Arthritis, represent a substantial market opportunity as patients seek better treatment regimens with reduced costs.

The GCC region's healthcare initiatives, aimed at improving patient access and outcomes, further bolster the importance of this segment, as it aligns with the goals of enhancing healthcare quality while controlling expenditures.Collectively, these applications stand out as critical drivers of innovation and growth within the biosimilars market, catering to the health demands of the population across the GCC.

GCC Biosimilar Contract Manufacturing Market Key Players and Competitive Insights:

The GCC Biosimilar Contract Manufacturing Market is experiencing dynamic changes driven by technological advancements, increasing healthcare needs, and a growing emphasis on cost-effectiveness in biopharmaceuticals. As the demand for biosimilars rises due to their potential in treating various chronic diseases, companies in this region are compelled to enhance their manufacturing capabilities while maintaining quality and regulatory standards.

Competitive insights highlight the strategies employed by key players in the market as they navigate a landscape characterized by rapid innovation and stringent regulations. The entry of new players alongside established firms complicates the competitive dynamics, leading to collaborations, partnerships, and contract agreements aimed at improving market share and operational efficiency.Sandoz stands out as a prominent player in the GCC Biosimilar Contract Manufacturing Market, leveraging its extensive experience and expertise in biopharmaceuticals.

The company's strengths lie in its robust portfolio of biosimilars, which are widely accepted in various therapeutic areas, including oncology and autoimmune diseases. Sandoz has established a strong market presence in the GCC region, supported by its commitment to high-quality manufacturing and adherence to regulatory standards. The firm utilizes advanced technologies that enhance the efficiency of its production processes while ensuring compliance with local regulations, which further solidifies its competitive position in the market.

This emphasis on quality and innovation positions Sandoz as a trusted partner for biosimilar contract manufacturing in the GCC.Teva Pharmaceuticals also holds a significant position within the GCC Biosimilar Contract Manufacturing Market, characterized by a diverse range of biosimilar products that address major health concerns in the region. The company has built a reputation for its strong manufacturing capabilities and robust supply chain management, enabling it to deliver high-quality biosimilars effectively.

Teva’s strategic focus on expanding its portfolio through mergers and acquisitions has resulted in a variety of biosimilar offerings tailored to the unique demands of the GCC market. This proactive approach not only strengthens Teva's market presence but also boosts its capacity to innovate and meet customer needs, positioning the company as a key player in the biosimilars segment. Additionally, Teva's collaboration with local firms enhances its operational footprint, further amplifying its presence in the competitive landscape of biosimilar contract manufacturing within the GCC.

Key Companies in the GCC Biosimilar Contract Manufacturing Market Include:

• Sandoz


• Teva Pharmaceuticals


• Merck KGaA


• Catalent


• Mylan


• Roche


• Amgen


• Samsung Biologics


• Lonza


• Wuxi Biologics


• AbbVie


• Genentech


• Fujifilm Diosynth Biotechnologies


• Pfizer


• Boehringer Ingelheim

GCC Biosimilar Contract Manufacturing Market Industry Developments

In recent months, the GCC Biosimilar Contract Manufacturing Market has experienced significant developments with various companies enhancing their presence in the region. Sandoz is focusing on expanding its manufacturing capabilities, engaging in local partnerships to bolster production capacity. Teva Pharmaceuticals has been investing in Research and Development to advance its biosimilar portfolio, while Merck KGaA is collaborating with regional organizations to access emerging markets more effectively. Moreover, Catalent's recent expansion in the UAE underlines the growing demand for biosimilars in the Gulf region. In terms of mergers and acquisitions, Mylan announced its acquisition of a manufacturing facility in Saudi Arabia in June 2023, reflecting robust market activity. Samsung Biologics is also planning to enhance its operational footprint in the GCC, catering to increasing local and international demand. Recent market valuations indicate a steady growth trajectory, as collaborative efforts are propelling innovation and production efficiency among companies such as AbbVie, Amgen, and Roche. This evolution aligns with governmental initiatives aimed at improving healthcare access, paving the way for a more competitive biosimilar landscape within the GCC over the past two years, particularly since early 2022.

GCC Biosimilar Contract Manufacturing Market Segmentation Insights

Biosimilar Contract Manufacturing Market Product Outlook

• Recombinant Non-glycosylated Proteins


• Recombinant Glycosylated Proteins

Biosimilar Contract Manufacturing Market Production Technology Outlook

• Mammalian


• Non-Mammalian

Biosimilar Contract Manufacturing Market Application Outlook

• Oncology


• Blood Disorders


• Growth Hormonal Deficiency


• Chronic & Autoimmune Disorders


• Rheumatoid Arthritis


• Others

 

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	227.54(USD Million)
MARKET SIZE 2024	270.55(USD Million)
MARKET SIZE 2035	1000.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	12.62% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Sandoz, Teva Pharmaceuticals, Merck KGaA, Catalent, Mylan, Roche, Amgen, Samsung Biologics, Lonza, Wuxi Biologics, AbbVie, Genentech, Fujifilm Diosynth Biotechnologies, Pfizer, Boehringer Ingelheim
SEGMENTS COVERED	Product, Production Technology, Application
KEY MARKET OPPORTUNITIES	Growing demand for affordable therapies, Expanding healthcare infrastructure investments, Increasing prevalence of chronic diseases, Rising popularity of personalized medicine, Regulatory support for biosimilars development
KEY MARKET DYNAMICS	regulatory support, rising healthcare costs, increasing demand for biologics, technological advancements, strategic partnerships
COUNTRIES COVERED	GCC